Pharmaceuticals

XPH released FY2025 Annual Earnings on April 28 After-Market (BJT), Actual Revenue: CNY 1.595 B, Actual EPS: CNY -2.11

XPH released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 449.49 M, actual EPS CNY -1.5488

XPH released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 354.16 M, actual EPS CNY -0.17

XPH FY2026 Q1 Earnings Release Scheduled for April 29 After-Market BJT

XPH to Release FY2025 Earnings on April 29 After-Market (BJT)

XPH released FY2025 Q3 earnings on October 27 After-Market BJT, actual revenue CNY 327.92 M, actual EPS CNY -0.2008

XPH released FY2025 9 Months earnings on October 27 After-Market (BJT), actual revenue CNY 1.146 B, actual EPS CNY -0.5517

XPH to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

XPH released FY2025 Q2 earnings on August 27 After-Market BJT, actual revenue CNY 396.99 M, actual EPS CNY -0.2209

XPH released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), actual revenue CNY 817.99 M, actual EPS CNY -0.35

XPH FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

ST Xiangxue 2024 Annual Report Shows Revenue and Profit Decline

XPH released FY2024 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 1.859 B, actual EPS CNY -1.3

XPH released FY2024 Q4 earnings on April 28 After-Market BJT, actual revenue CNY 325.1 M, actual EPS CNY -0.9682

XPH released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 421 M, actual EPS CNY -0.13

XPH FY2025 Q1 Earnings Release Scheduled for April 29 After-Market BJT

XPH to Release FY2024 Earnings Report on April 29, 2025, After-Market BJT

Scentpharm Enters Pre-Insolvency Reorganization Phase

ST Xiangxue Approved for Pre-reorganization, Temporary Manager Appointed

Xiangxue Pharmaceutical Penalized by CSRC for False Reporting, Stock Name Changed to ST Xiangxue

300147

On September 30th, ST XPH announced that the company's director and board secretary Xu Li applied to resign from the position of board secretary for personal reasons, with the resignation taking effect from the date it is delivered to the board of directors. After resigning from the above position, Xu Li will still serve as a director of the company. The 30th meeting of the 9th board of directors approved the proposal on the appointment of the board secretary, agreeing to appoint Xiang Jin as the board secretary of the company, with a term starting from the date of approval by this board meeting until the end of the 9th board's term

Zhitong

XPH: Xu Li resigned as the secretary of the board, Xiang Jin took over

According to the Zhitong Finance APP, XPH released its semi-annual report for 2025, showing an operating income of 818 million yuan, a year-on-year decrease of 25.40%. The net loss attributable to shareholders of the listed company was 234 million yuan, a year-on-year increase of 72.96%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 207 million yuan, a year-on-year increase of 91.43%. The basic loss per share was 0.35 yuan

XPH released its performance for the first half of the year, with a net loss attributable to the parent company of 234 million yuan, an increase of 72.96%

000597

China Galaxy Securities released a research report stating that cell gene therapy (CGT) has entered a period of realization of results, becoming the most promising development direction in the biopharmaceutical field. CGT has a high outsourcing ratio and high market concentration, with CXO expected to benefit first. Focus on companies with high pipeline maturity and good clinical trial data. Products such as CAR-T and TCR-T are being launched one after another, and the industry's prosperity continues to improve, with active investment and financing

NEPG

CNI BIOMEDICINE

China Galaxy Securities: Cell gene therapy has entered the stage of result realization, and CXO is expected to benefit first

The subsidiary of XPH, Xiangxue Life Sciences, has received approval from the National Medical Products Administration for the clinical trial application of the new drug TAEST1901 injection. This drug is suitable for the treatment of advanced gastric cancer with the genotype HLA-A*02:01 and positive expression of the tumor antigen AFP

XPH: TAEST1901 injection has received approval for clinical trials

XPH announced that the Guangzhou Intermediate People's Court has agreed to a 3-month pre-restructuring and has appointed King & Wood Mallesons (Guangzhou) and Guangdong Dongfang Kunlun Law Firm as temporary administrators. This decision does not represent the formal acceptance of Jinglong Construction's restructuring application by the Guangzhou Intermediate People's Court, and there remains uncertainty regarding the initiation of the restructuring process

XPH: Guangzhou Intermediate People's Court agrees to the company's pre-restructuring and appoints a temporary administrator

300343

300175

ST XPH, ST LECRON, and ST LONTRUE all resumed trading today with a 20% limit down. On the news front, Xiangxue Pharmaceutical, Lonyuan Co., and Lianchuang Co. issued a notice over the weekend regarding the implementation of other risk warnings

LECRON

LONTRUE

Other risk warnings implemented, ST XPH and 3 other stocks resume trading with a 20% limit down

XPH announced that the company and relevant parties received the "Advance Notice of Administrative Penalty" from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission. Due to false records and significant omissions in the 2019 annual report, the CSRC intends to impose a fine of 6 million yuan on the company, a fine of 10 million yuan on the actual controller Wang Yonghui, and implement a 5-year market ban

XPH: Received the "Notice of Administrative Penalty"

XPH has been subjected to other risk warnings by the China Securities Regulatory Commission due to false recording of financial indicators. According to relevant regulations, the company's stock will be suspended for 1 day on March 24, 2025, and will resume trading on March 25, at which time the stock abbreviation will be changed to "ST XPH"

XPH is subject to other risk warnings and will be suspended for trading for one day on March 24

XPH recently received a notice from creditor Jinglong Construction, stating that due to the failure to fulfill legal documents and the inability to repay due debts, Jinglong Construction has applied to the Guangzhou Intermediate People's Court for a pre-restructuring of the company. The court has issued a notification regarding this application

XPH was applied for pre-restructuring by creditor Jinglong Construction

000952

603229

301211

300723

The pharmaceutical sector has pulled back, with Ausun Pharm hitting the limit down, and BIOCAUSE HEILEN PHARMA, XPH, ApicHope, GUANGJI PHARMA, and several other stocks falling over 5%

XPH(300147.SZ)